BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 31904483)

  • 21. Immuno-PET Detects Antibody-Drug Potency on Coadministration with Statins.
    Brown EL; Shmuel S; Mandleywala K; Panikar SS; Berry NK; Rao Y; Zidel A; Lewis JS; Pereira PMR
    J Nucl Med; 2023 Oct; 64(10):1638-1646. PubMed ID: 37385676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development.
    Fujihara M; Shien T; Shien K; Suzawa K; Takeda T; Zhu Y; Mamori T; Otani Y; Yoshioka R; Uno M; Suzuki Y; Abe Y; Hatono M; Tsukioki T; Takahashi Y; Kochi M; Iwamoto T; Taira N; Doihara H; Toyooka S
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.
    Baselga J; Lewis Phillips GD; Verma S; Ro J; Huober J; Guardino AE; Samant MK; Olsen S; de Haas SL; Pegram MD
    Clin Cancer Res; 2016 Aug; 22(15):3755-63. PubMed ID: 26920887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Near-Infrared Photochemoimmunotherapy by Photoactivatable Bifunctional Antibody-Drug Conjugates Targeting Human Epidermal Growth Factor Receptor 2 Positive Cancer.
    Ito K; Mitsunaga M; Nishimura T; Saruta M; Iwamoto T; Kobayashi H; Tajiri H
    Bioconjug Chem; 2017 May; 28(5):1458-1469. PubMed ID: 28402624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting TACC3 Induces Immunogenic Cell Death and Enhances T-DM1 Response in HER2-Positive Breast Cancer.
    Gedik ME; Saatci O; Oberholtzer N; Uner M; Akbulut Caliskan O; Cetin M; Aras M; Ibis K; Caliskan B; Banoglu E; Wiemann S; Üner A; Aksoy S; Mehrotra S; Sahin O
    Cancer Res; 2024 May; 84(9):1475-1490. PubMed ID: 38319231
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trastuzumab emtansine (T-DM1) as adjuvant treatment of HER2-positive early breast cancer: safety and efficacy.
    Molinelli C; Parisi F; Razeti MG; Arecco L; Cosso M; Fregatti P; Del Mastro L; Poggio F; Lambertini M
    Expert Rev Anticancer Ther; 2021 Mar; 21(3):241-250. PubMed ID: 33245671
    [No Abstract]   [Full Text] [Related]  

  • 27. mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer.
    Casadevall D; Hernández-Prat A; García-Alonso S; Arpí-Llucià O; Menéndez S; Qin M; Guardia C; Morancho B; Sánchez-Martín FJ; Zazo S; Gavilán E; Sabbaghi MA; Eroles P; Cejalvo JM; Lluch A; Rojo F; Pandiella A; Rovira A; Albanell J
    Mol Cancer Res; 2022 Jul; 20(7):1108-1121. PubMed ID: 35348729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer.
    Sabbaghi M; Gil-Gómez G; Guardia C; Servitja S; Arpí O; García-Alonso S; Menendez S; Arumi-Uria M; Serrano L; Salido M; Muntasell A; Martínez-García M; Zazo S; Chamizo C; González-Alonso P; Madoz-Gúrpide J; Eroles P; Arribas J; Tusquets I; Lluch A; Pandiella A; Rojo F; Rovira A; Albanell J
    Clin Cancer Res; 2017 Nov; 23(22):7006-7019. PubMed ID: 28821558
    [No Abstract]   [Full Text] [Related]  

  • 29. HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors.
    Pegram MD; Miles D; Tsui CK; Zong Y
    Clin Cancer Res; 2020 Feb; 26(4):775-786. PubMed ID: 31582515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An anti-EGFR antibody-drug conjugate overcomes resistance to HER2-targeted drugs.
    Gandullo-Sánchez L; Pandiella A
    Cancer Lett; 2023 Feb; 554():216024. PubMed ID: 36455759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
    Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
    J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.
    Lu D; Li C; Riggs M; Polhamus D; French J; Agarwal P; Chen SC; Vadhavkar S; Patre M; Strasak A; Quartino A; Jin JY; Girish S
    Cancer Chemother Pharmacol; 2019 Jul; 84(1):175-185. PubMed ID: 31102024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2-Antibody-Drug Conjugate against Refractory HER2-Positive Cancers.
    Shin SH; Park YH; Park SS; Ju EJ; Park J; Ko EJ; Bae DJ; Kim SY; Chung CW; Song HY; Jang SJ; Jeong SY; Song SY; Choi EK
    Adv Sci (Weinh); 2021 Dec; 8(23):e2102414. PubMed ID: 34664433
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.
    English DP; Bellone S; Schwab CL; Bortolomai I; Bonazzoli E; Cocco E; Buza N; Hui P; Lopez S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Cancer Med; 2014 Oct; 3(5):1256-65. PubMed ID: 24890382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy of lapatinib in patients with metastatic HER2 positive breast cancer who received prior therapy with monoclonal antibodies and antibody-drug conjugate: a single institutional experience.
    Kolarov Bjelobrk I; Radic J; Trifunovic J; Pesic J; Vidovic V; Vranjkovic B; Petrovic N; Andrejic Visnjic B
    J Chemother; 2022 Jul; 34(4):264-271. PubMed ID: 34844517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of Acquired Resistance to Trastuzumab Emtansine in Breast Cancer Cells.
    Li G; Guo J; Shen BQ; Yadav DB; Sliwkowski MX; Crocker LM; Lacap JA; Phillips GDL
    Mol Cancer Ther; 2018 Jul; 17(7):1441-1453. PubMed ID: 29695635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
    von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
    Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual targeting of HER2-positive cancer with trastuzumab emtansine and pertuzumab: critical role for neuregulin blockade in antitumor response to combination therapy.
    Phillips GD; Fields CT; Li G; Dowbenko D; Schaefer G; Miller K; Andre F; Burris HA; Albain KS; Harbeck N; Dieras V; Crivellari D; Fang L; Guardino E; Olsen SR; Crocker LM; Sliwkowski MX
    Clin Cancer Res; 2014 Jan; 20(2):456-68. PubMed ID: 24097864
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesized Anti-HER2 Trastuzumab-MCC-DM1 Conjugate: An Evaluation of Efficacy and Cytotoxicity.
    Shafiee S; Mirzaei R; Salehi M; Jalili N; Taheri A; Farahmand L
    Iran J Immunol; 2023 Sep; 20(3):303-315. PubMed ID: 37434357
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The evolving role of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer with brain metastases.
    Dong R; Ji J; Liu H; He X
    Crit Rev Oncol Hematol; 2019 Nov; 143():20-26. PubMed ID: 31449983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.